Evidence map›Paper›PMID 21555366›Full record

ArticleCancer research2011

Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation.

Christos Polytarchou, Dimitrios Iliopoulos, Maria Hatziapostolou, Filippos Kottakis, Ioanna Maroulakou, Kevin Struhl, Philip N Tsichlis

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Human miRNAs in Cancer: Statistical Trends and Cross Kingdom Approach.International journal of molecular sciences · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Christos PolytarchouMolecular Oncology Research Institute, Tufts Medical Center, Boston, Massachusetts 02111, USA.
Dimitrios Iliopoulos
Maria Hatziapostolou
Filippos Kottakis
Ioanna Maroulakou
Kevin Struhl
Philip N Tsichlis
Molecular Oncology (United States) · USHarvard University · USTufts Medical Center · US

Funding

Genomic targets of oncoproteins and tumor suppressorsR01CA107486 · NCI · HARVARD MEDICAL SCHOOL · PI STRUHL, KEVIN · 2006 to 2020
$9.4M
Akt in T cell development and functionR01CA057436 · NCI · TUFTS MEDICAL CENTER · PI TSICHLIS, PHILIP N. · 1994 to 2011
$3.2M
NCI NIH HHS R01 CA057436NCI NIH HHS R01 CA107486NCI NIH HHS R01CA107486
6 · The paper itself

Abstract

The growth and survival of tumor cells in an unfavorable hypoxic environment depend upon their adaptability. Here, we show that both normal and tumor cells expressing the protein kinase Akt2 are more resistant to hypoxia than cells expressing Akt1 or Akt3. This is due to the differential regulation of microRNA (miR) 21, which is upregulated by hypoxia only in Akt2-expressing cells. By upregulating miR-21 upon oxygen deprivation, Akt2 downregulates PTEN and activates all three Akt isoforms. miR-21 also targets PDCD4 and Sprouty 1 (Spry1), and the combined downregulation of these proteins with PTEN is sufficient to confer resistance to hypoxia. Furthermore, the miR-21 induction by Akt2 during hypoxia depends upon the binding of NF-κB, cAMP responsive element-binding protein (CREB), and CBP/p300 to the miR-21 promoter, in addition to the regional acetylation of histone H3K9, all of which are under the control of Akt2. Analysis of the Akt2/miR-21 pathway in hypoxic MMTV-PyMT-induced mouse mammary adenocarcinomas and human ovarian carcinomas confirmed the activity of the pathway in vivo. Taken together, this study identifies a novel Akt2-dependent pathway that is activated by hypoxia and promotes tumor resistance via induction of miR-21.

Indexed as

Adaptor Proteins, Signal TransducingAdenocarcinomaAnimalsApoptosis Regulatory ProteinsCell HypoxiaEnzyme ActivationExtracellular Signal-Regulated MAP KinasesFemaleHumansIsoenzymesMammary Neoplasms, ExperimentalMembrane ProteinsMiceMicroRNAsOvarian NeoplasmsOxygenAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsExtracellular Signal-Regulated MAP KinasesIsoenzymesMembrane ProteinsMicroRNAsMIRN21 microRNA, humanMIRN21 microRNA, mouseOxygenPDCD4 protein, humanPdcd4 protein, mousePhosphoproteinsProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseRNA-Binding ProteinsSPRY1 protein, humanSpry1 protein, mouse

Identifiers

PMID21555366
PMCPMC3129420
OpenAlexW2137952489

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.